INNOTEST® NPTX2
INNOTEST NPTX2 is a solid-phase enzyme immunoassay for the quantitative determination of neuronal pentraxin-2 (NPTX2) in human cerebrospinal fluid (CSF).
Product number 80908
Product number 80909
Click here to navigate
- Contact sales for information
- Details
- Conditions of sale
- Documentation
- Insights
- FAQ
- Related products
- Product inquiry
-
Details
This assay should be used in combination with the NPTX2 CAL-RVC pack, article no. 80909 (RUO), of the corresponding lot.
Test principle
The INNOTEST NPTX2 is a solid-phase enzyme immunoassay in which the neuronal pentraxin-2 protein is captured by a first monoclonal antibody, 33F9 (ADx409; IgG1). CSF samples are added and incubated with a biotinylated antibody, 22H10 (ADx410; IgG2a). This antigen-antibody complex is then detected by a peroxidase-labeled streptavidin. After addition of substrate working solution, samples will develop a color. The color intensity is a measure for the amount of human neuronal pentraxin-2 protein in the sample1,2.
Test principle INNOTEST NPTX2 (SV= streptavidin; HRP= horseradish peroxidase).
BackgroundNeuronal pentraxin-2 is a synaptic protein that consistently shows decreased CSF concentrations in Alzheimer’s disease compared to control subjects1,2. Preliminary studies indicate that while CSF NPTX2 correlates poorly with the core CSF biomarkers (β-amyloid and tau) and other synaptic markers, it seems to correlate well with cognitive decline2.
References
- Jacobs D, et al. A monoclonal antibody based immunoassay for Neuronal Pentraxin2 in CSF. ADPD 2019.
- Vanmechelen E, et al. NPTX2 levels in CSF as potential predictor of cognitive dysfunction in the AD continuum. AAIC 2019.
-
Conditions of sale
To read the end user conditions of sale for this product please visit our Resource center.
-
Documentation
Browse regulatory documents for this product
Create a (free!) eServices account and start browsing all regulatory documentation right away.
Other documents
Get access to this section and more
Create a free eServices account now and instantly access multiple digital resources:
- Regulatory product documentation
- Selected scientific posters
- Product leaflets
- How-to videos and more…
-
Insights
Jan 4, 2023 -
FAQ
How does the coronavirus disease Covid-19 impact Fujirebio's operations?Please see the following statement on the impact of coronavirus disease Covid-19 on the operations of Fujirebio Europe (updated January 19, 2021).
-
Related products
-
Product inquiry